goodrx wegovy - Search News

News

GoodRx, Ozempic and Novo Nordisk

Fast Company · 2d

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk’s breakup with Hims

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

The Hill on MSN · 22h

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month’s supply of Novo Nordisk’s semaglutide pen products for $499 through GoodRx.

The Pharma Letter · 1d

GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month.

ConsumerAffairs1h

GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

StockStory.org on MSN15m

Noodles, GoodRx, Micron, Custom Truck One Source, and CarMax Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this ...

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies ...

How GoodRx CEO Wendy Barnes is trying to halve the cost of GLP-1 obesity drugs

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Novo Nordisk stock rises, Wegovy approved to treat liver disease

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

23h

What's Going On With Hims & Hers Shares Today?

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results